Taking varenicline for smoking cessation: A rare cause of pulmonary thromboembolism with infarction

Sun Hwa Lee, Seong Jong Yun, Seokyong Ryu, Seung Won Choi, Hye Jin Kim, Tae Kyug Kang, Sung Chan Oh, Suk Jin Cho

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Varenicline (Champix®, Chantix®) is a partial agonist of the α4β2 nicotinic acetylcholine receptor (nAChR) and a full agonist of the α7 nAChR. It has been used for smoking cessation since 2006. Varenicline has been associated with adverse cardiovascular (CV) events, including myocardial infarction, which may be caused by activation of the α7 nAChR receptor that in turn stimulates parasympathetic output from the brainstem to the heart, release of catecholamines, and has a prothrombotic effect. However, among the adverse CV events, the issue related to the varenicline-induced pulmonary thromboembolism (PTE) has not being addressed. We report a case of PTE with pulmonary infarction presenting as right flank pain that resulted from the use of varenicline (the total score of adverse drug reaction probability scale, 6; probable association between varenicline and pulmonary PTE) in a patient without underlying CV disease and in whom low probability of PTE (Wells score was zero) was identified.

Original languageEnglish
Pages (from-to)1037.e3-1037.e6
JournalAmerican Journal of Emergency Medicine
Issue number7
StatePublished - Jul 2017

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Inc.


  • Adverse reaction
  • Pulmonary infarction
  • Pulmonary thromboembolism
  • Smoking cessation
  • Varenicline


Dive into the research topics of 'Taking varenicline for smoking cessation: A rare cause of pulmonary thromboembolism with infarction'. Together they form a unique fingerprint.

Cite this